RxDoctor Payments Data

Ann Woolley, MD

Infectious Disease · Boston, MANPI 1205157625

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,729 of the $11,580 with a category attached, or 84.0%. 8 manufacturers reported payments, led by Abbott at 49.9% of the total. Among infectious disease clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,580in general payments, 2019–2025

Across 20 payments — averaging $578.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • La Jolla Pharmaceutical Company$2K
  • Philips North America LLC$1K
  • Paragonix Technologies, Inc.$1K
  • Intervascular$655
  • Takeda Pharmaceuticals U.S.A., Inc.$210
  • plus $267 from 2 others
$27,973in research payments, 2019–2025

Across 2 payments — averaging $13,987 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • 60 Degrees Pharmaceuticals$28K

What the payments were for

  • Consulting fees$9,72984%
  • Speaking & faculty fees$1,0009%
  • Travel & lodging$500%
  • Food & beverage$8017%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,580 in reported general payments places this provider in the 90th percentile of 368 infectious disease providers in Massachusetts.

See all infectious disease providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$51,042
Medicare patients
156
Services billed
366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala13$56,230
Vancomycin Hcl36$5,629
Cefepime Hcl12$1,535

Paid to pharmacies, not to this prescriber.

Other infectious disease in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →